NASDAQ:IMUX
Immunic Inc. Stock News
$1.29
+0.0450 (+3.61%)
At Close: May 20, 2024
Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April
06:30am, Tuesday, 13'th Apr 2021
NEW YORK, April 13, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chron
Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic's Lead Program, IMU-838
08:50am, Wednesday, 31'st Mar 2021
NEW YORK and PLANEGG-MARTINSRIED, Germany, March 31, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology
Immunic Gets Bullish Rating On Multiple Sclerosis Drug Prospect
12:26pm, Wednesday, 24'th Mar 2021
Immunic Inc's (NASDAQ: IMUX) lead candidate, IMU-838, has an “attractive safety profile” and exhibited positive efficacy results in the Phase II trials, according to JMP Securities. The Immunic An
7 Beaten Down Stocks With Insider Buying
03:39pm, Tuesday, 23'rd Mar 2021
A simple yet effective way to screen stocks for investment ideas is to look at what the insiders are doing, and to keep an eye out for insider buying. The insiders are the people in a company who have
Immunic, Inc. to Participate in Industry and Investor Conferences in March
06:30am, Tuesday, 02'nd Mar 2021
NEW YORK, March 2, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic
Immunic, Inc. Reports Year End 2020 Financial Results and Highlights Recent Activity
06:30am, Friday, 26'th Feb 2021
NEW YORK, Feb. 26, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic
Immunic's IMU-838 Shows Promising Clinical Effect In Mid-Stage Liver Disease Study
08:26am, Thursday, 18'th Feb 2021
Immunic Inc (NASDAQ: IMUX) has announced top-line data from an investigator-sponsored Phase 2 proof-of-concept trial evaluating IMU-838 in primary sclerosing cholangitis (PSC), a rare liver dise
NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic
IMU-838 Data In COVID-19 Study Fails To Cheer Immunic Investors; Stock Tanks
08:49am, Wednesday, 17'th Feb 2021
Immunic Inc (NASDAQ: IMUX) completes the main analysis of Phase 1 CALVID-1 trial evaluating its lead asset, IMU-838. It is a selective oral DHODH inhibitor used in hospitalized patients with mod
Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial
06:30am, Wednesday, 17'th Feb 2021
NEW YORK, Feb. 17, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic
Immunic, Inc. to Participate in Investor Conferences in January
06:30am, Tuesday, 05'th Jan 2021
NEW YORK, Jan. 5, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic i
Immunic, Inc. Added to NASDAQ Biotechnology Index
06:30am, Monday, 14'th Dec 2020
NEW YORK, Dec. 14, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic
Immunic, Inc. Announces Formation of Scientific-Medical Advisory Board
06:30am, Tuesday, 17'th Nov 2020
NEW YORK, Nov. 17, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic
Immunic, Inc. to Participate in Investor and Scientific Conferences in November
06:30am, Tuesday, 10'th Nov 2020
NEW YORK, Nov. 10, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic
NEW YORK, Nov. 2, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic i
